Semaglutide Plus Bariatric Surgery Led to Severe Nerve Damage From Nutrient Deficiencies

Single clinical case report. The patient underwent physical examination, laboratory serum testing for micronutrients, and lumbar MRI. Diagnosis was made based on the combination of neurological findings, documented nutrient deficiencies, and absence of structural abnormalities on imaging.

Millions of people are now using GLP-1 receptor agonists like semaglutide, and many have a history of or are considering bariatric surgery. This case highlights a potentially dangerous blind spot: there are established nutritional monitoring guidelines for bariatric surgery patients but almost none for GLP-1RA users, and no guidelines at all for patients using both. As combination weight-loss approaches become more common, nutrient monitoring becomes critical.

The explosion of GLP-1 receptor agonist prescribing has created new clinical scenarios that weren't anticipated in original trials. Combining potent appetite suppressants with malabsorptive surgeries creates compound nutritional risk. This case is likely a sentinel event — as more post-bariatric patients receive semaglutide, similar complications may emerge, underscoring the need for specific monitoring guidelines.

This is a single case report, representing the lowest level of clinical evidence. The relative contribution of bariatric surgery versus semaglutide to the nutrient deficiencies cannot be determined. The patient's dietary intake and compliance with post-surgical nutrition recommendations were not detailed. It's unclear whether semaglutide alone (without prior surgery) would pose similar risks. Long-term neurological outcomes were not reported.